--- title: "Jonathan S Katz, M.D. | Sutter Health" url: "https://www.sutterhealth.org/research/investigators/jonathan-s-katz-md-1049681078" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Investigators](https://www.sutterhealth.org/research/investigators) / 4. Jonathan S Katz, M.D. ![Jonathan S Katz, M.D.](https://dyn.mktgcdn.com/p/e5XrnYB0_0NPm8BW1zudPpb9L7b73YitfpxL6zIxknY/fit=crop,gravity=auto,dpr=2,width=240,height=240) # Jonathan S Katz, M.D. Investigator [View profile](https://www.sutterhealth.org/find-provider/dr-jonathan-s-katz-1046237524) Dr. Katz studies amyotrophic lateral sclerosis (ALS), myasthenia gravis, neuromuscular diseases, pain management, peripheral neuropathy, poliomyelitis, radiculopathies, and spinal muscular atrophy. He leads clinical trials of pharmacotherapies to slow the progression of ALS; device trials; a study of the NeuRX Diaphragm Pacing System to support patients with diaphragm weakness; and observational studies of factors affecting disease progression. Dr. Katz and others at the Forbes Norris Center work with researchers at the University of California, San Diego, to study mutations in RNA binding proteins that cause neuronal dysfunction and death. In 2014, Dr. Katz and colleagues at CPMC collaborated with Cedars-Sinai Regenerative Medicine Institute on new stem cell and gene therapy techniques to treat ALS patients. He is President of the ALS Research Group—an international ALS research collaboration. He sits on the medical advisory board for GBS-CIDP Foundation International and the Myasthenia Gravis Association. ## Research studies - Research study ### [Amyotrophic Lateral Sclerosis (ALS) CAPTURE](https://www.sutterhealth.org/research/studies/create-capture-1049141876) Clinical Procedures to Support Research in ALS (CAPTURE-ALS) - Research study ### [Chronic Inflammatory Demyelinating Polyneuropathy Registry VRCIDP 5166-Vitaccess-CIDP-01](https://www.sutterhealth.org/research/studies/chronic-inflammatory-demyelinating-polyneuropathy-registry-vrcidp-5166-vitaccess-cidp-01-2064309821) Vitaccess Real CIDP Registry: A Prospective International Observational Patient Registry in Chronic Inflammatory Demyelinating Polyneuropathy Linking Clinical and Patient-Reported Data 5166-Vitaccess-CIDP-01 ## Clinical trials - Clinical trial ### [ALS Healey Platform Trial Master Protocol](https://www.sutterhealth.org/research/clinical-trials/als-healey-platform-trial-master-protocol-2057369170) HEALEY ALS Platform Trial **Status:** Closed to Enrollment - Clinical trial ### [Amyotrophic Lateral Sclerosis (ALS) C302-CLN-2301](https://www.sutterhealth.org/research/clinical-trials/amyotrophic-lateral-sclerosis-als-c302-cln-2301-2044044761) Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) **Status:** Open to Enrollment - Clinical trial ### [Amyotrophic Lateral Sclerosis (ALS) PL101-ALS301 PREVAILS](https://www.sutterhealth.org/research/clinical-trials/amyotrophic-lateral-sclerosis-als-pl101-als301-prevails-2064309735) A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis **Status:** Open to Enrollment - Clinical trial ### [Amyotrophic Lateral Sclerosis (ALS) UNITE-ALS USNO.24.002](https://www.sutterhealth.org/research/clinical-trials/amyotrophic-lateral-sclerosis-als-unite-als-usno24002-2064309948) A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Usnoflast Administered to Adult Subjects With ALS UNITE-ALS USNO.24.002 **Status:** Open to Enrollment - Clinical trial ### [Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IMVT-1402-2401](https://www.sutterhealth.org/research/clinical-trials/chronic-inflammatory-demyelinating-polyneuropathy-cidp-imvt-1402-2401-2044041761) A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) **Status:** Open to Enrollment Page 1 of 2 ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/investigators/jonathan-s-katz-md-1049681078#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Investigators","item":"https://www.sutterhealth.org/research/investigators"},{"@type":"ListItem","position":4,"name":"Jonathan S Katz, M.D."}]} ``` ```json {"@context":"https://schema.org","@type":"ProfilePage","@id":"https://www.sutterhealth.org/research/investigators/jonathan-s-katz-md-1049681078#profilepage","url":"https://www.sutterhealth.org/research/investigators/jonathan-s-katz-md-1049681078","name":"Jonathan S Katz, M.D.","dateModified":"2026-06-04","breadcrumb":{"@id":"https://www.sutterhealth.org/research/investigators/jonathan-s-katz-md-1049681078#breadcrumblist"},"primaryImageOfPage":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/e5XrnYB0_0NPm8BW1zudPpb9L7b73YitfpxL6zIxknY/460x460.webp","width":460,"height":460},"mainEntity":{"@id":"https://www.sutterhealth.org/research/investigators/jonathan-s-katz-md-1049681078"}} ``` ```json {"@context":"https://schema.org","@type":"Person","@id":"https://www.sutterhealth.org/research/investigators/jonathan-s-katz-md-1049681078","name":"Jonathan S Katz, M.D.","givenName":"Jonathan","additionalName":"S","familyName":"Katz","honorificSuffix":"M.D.","description":"Dr. Katz studies amyotrophic lateral sclerosis (ALS), myasthenia gravis, neuromuscular diseases, pain management, peripheral neuropathy, poliomyelitis, radiculopathies, and spinal muscular atrophy. He leads clinical trials of pharmacotherapies to slow the progression of ALS; device trials; a study of the NeuRX Diaphragm Pacing System to support patients with diaphragm weakness; and observational studies of factors affecting disease progression. Dr. Katz and others at the Forbes Norris Center work with researchers at the University of California, San Diego, to study mutations in RNA binding proteins that cause neuronal dysfunction and death. In 2014, Dr. Katz and colleagues at CPMC collaborated with Cedars-Sinai Regenerative Medicine Institute on new stem cell and gene therapy techniques to treat ALS patients. He is President of the ALS Research Group—an international ALS research collaboration. He sits on the medical advisory board for GBS-CIDP Foundation International and the Myasthenia Gravis Association.","image":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/e5XrnYB0_0NPm8BW1zudPpb9L7b73YitfpxL6zIxknY/460x460.webp","representativeOfPage":true},"affiliation":{"@id":"https://www.sutterhealth.org/#medicalorganization"},"mainEntityOfPage":{"@id":"https://www.sutterhealth.org/research/investigators/jonathan-s-katz-md-1049681078#profilepage"},"sameAs":"https://www.sutterhealth.org/find-provider/dr-jonathan-s-katz-1046237524"} ```